Valuation, from the filing
| Public float | $25.03B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $185.63 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 22.9× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 3.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 3.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
22.9× earnings today, against a median of 19.3× across 10 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $25.03B | 22.9× | |
| 2024-06-30 | $24.71B | 9.2× | |
| 2023-06-30 | $20.56B | 19.5× | |
| 2022-06-30 | $17.35B | 16.3× | |
| 2021-06-30 | $21.61B | 19.2× | |
| 2020-06-30 | $13.86B | 20.3× | |
| 2019-06-30 | $14.53B | 21.4× | |
| 2018-06-30 | $10.78B | 18.9× | |
| 2017-06-30 | $12.39B | 15.3× | |
| 2016-06-30 | $10.67B | 21.0× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
DOVER Corp (DOV) reported revenue of $8.58B and net income of $1.17B for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from DOVER Corp’s SEC filings, each linked to the filing it came from.
Income
| Metric | 2026-09-30 |
|---|---|
| Revenue | $8.58B |
| Cost of revenue | $5.17B |
| Gross profit | $3.40B |
| Operating income | $1.46B |
| Net income | $1.17B |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | $284.94M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $1.94B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-09-30 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $13.68B |
| Current assets | $4.96B |
| Total liabilities | Unavailable |
| Current liabilities | $2.55B |
| Total equity incl. NCI | $7.64B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $1.47B |
| Accounts receivable | $1.57B |
| Goodwill | $5.38B |
| Long-term debt | $2.58B |
| Accounts payable | $943.34M |
Cash flow
| Metric | 2026-09-30 |
|---|---|
| Operating cash flow | Unavailable |
| Capital expenditures | $219.99M |
| Investing cash flow | Unavailable |
| Financing cash flow | -$985.88M |
| Net change in cash | $140.37M |
| Stock-based compensation | $39.79M |
| Common dividends paid | $280.61M |
| Common share repurchases | $885.53M |
| Depreciation & amortization | $391.52M |
Derived
| Metric | 2026-09-30 |
|---|---|
| Free cash flow | Unavailable |
| Gross margin | 39.7% |
| Operating margin | 17.0% |
| FCF margin | Unavailable |
| SBC / revenue | 0.5% |
| Current ratio | 1.95x |
| Revenue YoY growth | 8.2% |
| Net margin | 13.6% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 2.6% |
| Long-term debt / equity | 0.34x |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DOV in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.